You are here

Non-Approvable Letter Issued for Memantine To Treat Mild Alzheimer's Disease

NEW YORK, July 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that the United States Food and Drug Administration (FDA) has issued a non-approvable letter in response to its supplemental New Drug Application (sNDA) to expand the indication of Namenda (memantine HCl) to include treatment of mild Alzheimer's disease. Namenda was approved by the FDA for the treatment of moderate to severe Alzheimer's disease in October 2003.

The FDA accepted the sNDA for review in November 2004. Upon completing its review, the FDA acknowledged that it had informed Forest that a single positive study in patients with mild to moderate Alzheimer's disease would be adequate to support extending Namenda's claim to include mild patients. The FDA further acknowledged that the six-month, U.S., mild to moderate study which reached statistical significance at the required primary endpoints was such a study. Nevertheless the FDA decided not to approve Namenda for mild patients based upon this single positive study in light of two previously disclosed, additional studies of Namenda in patients with mild to moderate Alzheimer's disease -- a study of Namenda monotherapy conducted by H. Lundbeck in Europe and a combination study conducted by Forest in the U.S. with Namenda administered to patients already taking an acetylcholinesterase inhibitor. In both of these studies, which were included in the sNDA filing, Namenda performed numerically better than placebo; however, statistical significance was not reached at the primary endpoints. In all three studies, Namenda was found to be well tolerated. Forest plans to meet with the FDA to further discuss the non-approvable letter. The Company also indicated that the non- approvable status of Namenda for mild Alzheimer's disease would not impact its current earnings per share guidance of $2.30 for the fiscal year ending March 31, 2006.

Namenda is currently approved for the treatment of moderate to severe Alzheimer's disease. "Namenda offers a well tolerated and effective treatment option to the millions of Americans suffering with moderate or severe Alzheimer's disease," said Ivan Gergel, M.D., Senior Vice President of Scientific Affairs at Forest Laboratories and President of Forest Research Institute. "As the only approved treatment option for patients who have progressed beyond the moderate stage of disease, and as a first-line therapy that can be used alone or in combination with other approved treatments, Namenda plays a very important role in the Alzheimer's disease treatment paradigm."

About Alzheimer's Disease
Alzheimer's is a progressive disease of the brain and the most common type of dementia. Dementia is used to describe the progressive loss of cognitive, intellectual, or functional abilities. Published reports project that by 2050 more than 16 million people in the United States will have Alzheimer's disease. Currently, all Alzheimer's medications approved in the United States other than Namenda belong to a class of agents called acetylcholinesterase inhibitors, and are indicated only for patients with mild to moderate symptoms of the disease. Namenda can be used alone or in combination with an acetylcholinesterase inhibitor for moderate- and severe-stage patients.

About Namenda
Namenda (memantine HCl) is the first in a class of medications with a unique mechanism of action that focuses on the glutamate pathway, a target for the treatment of Alzheimer's disease. Indicated for the treatment of moderate to severe Alzheimer's disease, the FDA approved Namenda in October 2003 based on three studies of Namenda used alone or in combination with another Alzheimer's disease drug.

Namenda is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with Namenda vs placebo (greater than or equal to 5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, dosage should be reduced.

Source: Forest Laboratories, Inc.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs